Trypsin-Chymotrypsin in Menstrual Pain (Dysmenorrhea)

What Is It?

Mechanism of Action

1. Proteolysis of inflammatory mediators - The enzymes break down kinins (bradykinin), fibrin, and other pro-inflammatory proteins that accumulate at sites of tissue injury and inflammation, including the inflamed endometrium and pelvic tissues during menstruation.
2. Reduction of edema - By breaking down protein-rich exudate, the enzymes reduce local tissue swelling and pelvic congestion, which contributes to dysmenorrheal cramping.
3. Fibrinolysis - Trypsin activates plasminogen to plasmin, promoting breakdown of fibrin clots. This helps improve local microcirculation in the uterine and pelvic vasculature, alleviating ischemic pain.
4. Increased blood flow - Reduced edema and fibrin deposition allow increased blood supply to the uterus, which counteracts the hypoxia-driven cramping that is central to primary dysmenorrhea.
5. Prostaglandin modulation (indirect) - By reducing the overall inflammatory milieu (kinin and fibrin load), the enzymes may indirectly reduce prostaglandin-driven uterine hypercontractility, though they do not directly inhibit cyclooxygenase like NSAIDs do.
6. Antibiotic potentiation - An additional benefit in secondary dysmenorrhea associated with pelvic infection: these enzymes enhance antibiotic penetration to the site, which helps when dysmenorrhea is related to pelvic inflammatory disease (PID).

Role in Dysmenorrhea - Primary vs Secondary

Dosage

• Standard dose: 1 tablet (50,000 AU) 4 times daily, taken 30 minutes before meals on an empty stomach
• Enteric coating is essential - protects the enzyme from gastric acid; must not be crushed or chewed
• Onset of action: approximately 30 minutes after absorption in the small intestine
• Course: typically 7-10 days; not for long-term use

Contraindications

• Severe hepatic insufficiency
• Renal impairment
• Peptic ulcer disease
• High intraocular (vitreous) pressure
• Known hypersensitivity to trypsin or chymotrypsin
• Pregnancy - avoid, especially in first 3 months (insufficient safety data)
• Within 1 week after pulmonary hemorrhage
• Blood clotting disorders

Drug Interactions

• Anticoagulants (warfarin/coumadin, heparin, clopidogrel) - increased bleeding risk; avoid combination
• Chloramphenicol - enzyme may affect antibiotic levels

Side Effects

• Nausea, diarrhea, abdominal discomfort (most common, usually mild)
• Skin rash, itching
• Rarely: allergic reaction (urticaria, angioedema, bronchospasm, anaphylaxis)
• Tendency toward bleeding with prolonged use

Clinical Perspective

• Women who need additional anti-inflammatory support alongside NSAIDs
• Post-gynecological surgical pain (episiotomy, cesarean section)
• Secondary dysmenorrhea with a significant inflammatory or fibrinous component
• Situations where reducing pelvic edema and improving microcirculation is the therapeutic goal

Menstrual Disorders: Hypomenorrhea, Dysmenorrhea & Trypsin-Chymotrypsin

1. HYPOMENORRHEA (Scanty Menstruation)

Definition

Note: "Hymenorrhea" is not a standard medical term. The likely intended term is hypomenorrhea.

Causes

• Perimenopause (declining estrogen)
• Significant weight loss, malnutrition, eating disorders
• Extreme athletic training

Investigations

• Hormones: FSH, LH, estradiol, prolactin, TSH, androgens (to screen PCOS)
• Pelvic ultrasound: Endometrial thickness, ovarian morphology, follicular tracking
• Hysteroscopy / SIS (saline infusion sonography): Gold standard for intrauterine adhesions (Asherman's)
• MRI: For detailed uterine anatomy when ultrasound is equivocal
• D&C / endometrial biopsy: If neoplasia suspected

Treatment

• Hormonal: Estrogen therapy (to proliferate thin endometrium) ± progestin cycling
• Structural: Hysteroscopic adhesiolysis for Asherman's; followed by estrogen to promote re-epithelialization
• OCP-related: Reassure if asymptomatic; switch formulation if desired
• Thyroid/prolactin correction: Address underlying cause

2. DYSMENORRHEA (Painful Menstruation)

Definition

Classification

Pathophysiology of Primary Dysmenorrhea

1. Intense uterine smooth muscle contractions (mainly from PGF2α)
2. Decreased uterine blood flow → ischemia → anaerobic metabolite accumulation
3. Increased peripheral nerve hypersensitivity → pain sensitization

Causes of Secondary Dysmenorrhea

• Endometriosis (most common) - ectopic endometrium responds to hormones, causes scarring and inflammation
• Adenomyosis - endometrial glands within myometrium
• Uterine fibroids (submucosal > intramural)
• Endometrial polyps
• Pelvic inflammatory disease (PID)
• Cervical stenosis
• Ovarian cysts
• Intrauterine device (copper IUD)

Treatment of Dysmenorrhea

• NSAIDs (ibuprofen 400-800 mg, mefenamic acid, naproxen, diclofenac): Directly inhibit COX → reduce PGF2α → decrease intrauterine pressure and pain. Most effective when started 1-2 days before expected onset.
• Combined oral contraceptive pills (COCPs): Suppress ovulation → thin endometrium → reduced PG production

• Progestin-only methods (Mirena IUD, norethisterone)
• GnRH agonists (for severe endometriosis/adenomyosis)
• Danazol

• Heat therapy (hot water bottle, heat patches)
• Transcutaneous electrical nerve stimulation (TENS)
• Exercise, dietary omega-3 fatty acids
• Laparoscopy for endometriosis (surgical)

3. TRYPSIN-CHYMOTRYPSIN IN MENSTRUAL DISORDERS

What It Is

Mechanism Relevant to Menstrual Pain

Where It Fits

• Primary dysmenorrhea: Used as an adjunct to NSAIDs - does not inhibit COX/prostaglandins directly, but reduces the kinin-edema-fibrin component of pain. Especially useful when NSAIDs alone give incomplete relief.
• Secondary dysmenorrhea (PID, adhesions): More directly applicable - reduces fibrinous exudate, prevents/treats adhesions, potentiates antibiotics.
• Post-gynecological surgery (episiotomy, cesarean, pelvic surgery): Directly indicated for post-operative edema and pain reduction.
• Hypomenorrhea from Asherman's: Trypsin-chymotrypsin's anti-adhesion and fibrinolytic properties are relevant here - it can help reduce fibrinous adhesion re-formation after hysteroscopic adhesiolysis (though the primary treatment remains hormonal + surgical).

Dose for Menstrual Indications

• 1 tablet (50,000 AU) 4 times daily, taken 30 minutes before meals
• Duration: 7-10 days per treatment course
• Must be swallowed whole (enteric-coated - do not crush)

Contraindications (Important for Gynaecology)

• Pregnancy (especially first trimester) - avoid; insufficient safety data
• Breastfeeding - avoid
• Severe liver or kidney disease
• Peptic ulcer
• Active bleeding / coagulopathy
• Concurrent anticoagulants (warfarin, heparin, clopidogrel) - increased bleeding risk

Putting It All Together

Leuprolide 3.75 mg on Day 1 - Effect on Menstrual Flow

What Leuprolide 3.75 mg Is

Why It Is Given on Day 1 of the Cycle

• Ensure the patient is not pregnant
• Synchronize the start of treatment with the low-estrogen phase (just as the new follicular phase begins)
• Minimize the risk of the initial "flare" contributing to a prolonged estrogen surge

Mechanism: The Two-Phase HPO Axis Effect

Phase 1 - Initial FLARE (Days 1 to ~7-14)

• FSH and LH both spike within hours to days
• This drives estrogen (estradiol) to rise transiently - sometimes to levels seen mid-cycle
• Result: The endometrium, already being shed during Day 1 menstruation, may experience temporarily heavier or prolonged bleeding in that first cycle, or irregular spotting
• This is the "flare effect" or "flare response"

Pharmacokinetically, a single IM depot injection of 3.75 mg produces a peak plasma leuprolide level within ~3 hours, then maintains steady levels for 4-5 weeks. The estradiol suppression for individual subjects begins anywhere between Day 4 and Week 4 after the injection. - Abbott/NAFDAC product monograph

Phase 2 - Downregulation and Suppression (Weeks 2-4 onward)

• FSH and LH levels fall dramatically
• Estradiol falls to menopausal range (< 20-30 pg/mL, mean ~8 pg/mL) by Week 3
• Ovarian follicular development ceases → anovulation
• Endometrium becomes thin and atrophic from estrogen deprivation
• Menstrual flow progressively decreases and stops

"After 2-3 weeks, desensitization and pituitary downregulation result in a hypogonadotropic, hypogonadal state." - Goodman & Gilman's Pharmacological Basis of Therapeutics

Timeline of Menstrual Changes After Day 1 Injection

Data from Lupron Depot clinical trial data (Prescriber Point / FDA labeling).

Additional Menstrual Effects of Clinical Importance

• Uterine fibroids: In fibroid patients, excessive bleeding (menorrhagia/menometrorrhagia) decreased in 80% of women at 3 months. Uterine volume and myoma volume reduced by ≥25% in 54-60% of patients.
• Endometriosis: Suppression of ectopic endometrial implants → relief of dysmenorrhea and non-menstrual pelvic pain.
• Anemia correction: Used with iron supplementation pre-operatively; hematocrit ≥36% achieved in 75% of women by Week 12 (vs 49% with iron alone).

Important Warnings

Summary in One Flow

Day 1 Injection (IM depot 3.75 mg)
    ↓
Flare: FSH/LH/Estradiol surge (Days 1-14)
    → Possible heavier bleed or spotting in current cycle
    ↓
Weeks 2-3: Pituitary receptor downregulation
    → FSH/LH fall → Estradiol → menopausal range (~8 pg/mL)
    ↓
Month 1: 74% amenorrhea
Month 2: 98% amenorrhea → Endometrial atrophy → NO FLOW
    ↓
After stopping: Menses return within 2-3 months (95% by Month 3)